NeoGenomics (NEO) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook

NeoGenomics (NASDAQ: NEO) reported Q3 EPS of $0.04, $0.01 better than the analyst estimate of $0.03. Revenue for the quarter came in at $60.8 million versus the consensus estimate of $61 million.

GUIDANCE:

NeoGenomics sees FY2016 EPS of $0.14-$0.16, versus prior guidance of $0.08-$0.13 and the consensus of $0.13. NeoGenomics sees FY2016 revenue of $245-250 million, versus the consensus of $247.0 million.

For earnings history and earnings-related data on NeoGenomics (NEO) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• Pfizer lung cancer drug misses survival goal in Phase 3 trial